Literature DB >> 20948207

Association of a functional polymorphism in the MMP-3 gene with Moyamoya Disease in the Chinese Han population.

Hao Li1, Zheng-Shan Zhang, Wei Liu, Wei-Zhong Yang, Zhen-Nan Dong, Mai-Juan Ma, Cong Han, Hong Yang, Wu-Chun Cao, Lian Duan.   

Abstract

BACKGROUND: Moyamoya disease (MMD) is an uncommon cerebrovascular disease characterized by progressive stenosis of the intracranial internal carotid arteries and their proximal branches. The important role of genetic factors in the etiology and pathogenesis of MMD is being increasingly recognized. The study was designed to examine the association of single nucleotide polymorphisms in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinase (TIMP) genes with MMD occurrence.
METHODS: A case-control study was performed. Five functional promoter polymorphisms in the MMP-2, MMP-3, MMP-9 and MMP-13 genes and a potentially functional promoter polymorphism in the TIMP-2 gene were determined by polymerase chain reaction-restriction fragment length polymorphism. Their associations with MMD were analyzed by multivariate logistic regression.
RESULTS: In total, 208 definite patients with MMD (including 31 familial MMD, FMMD, patients) and 224 healthy subjects were recruited. The frequency of the MMP-3 5A/6A and 5A/5A genotypes was significantly lower in MMD patients (OR = 0.57, 95% CI 0.38-0.86, p(corr) = 0.042) compared with healthy controls in a dominant genetic model. Significant differences of the MMP-3 5A/6A polymorphism were also detected between FMMD patients and controls both in the dominant genetic model (OR = 0.23, 95% CI 0.08-0.68, p(corr) = 0.048) and the additive genetic model (OR = 0.24, 95% CI 0.08-0.69, p(corr) = 0.048).
CONCLUSION: The functional polymorphism in the MMP-3 promoter might be associated with susceptibility to both MMD and FMMD in the Chinese Han population. The findings need to be validated in further studies including more subjects from different populations.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20948207     DOI: 10.1159/000319893

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  11 in total

Review 1.  Twisted blood vessels: symptoms, etiology and biomechanical mechanisms.

Authors:  Hai-Chao Han
Journal:  J Vasc Res       Date:  2012-03-14       Impact factor: 1.934

Review 2.  Genetic and Proteomic Contributions to the Pathophysiology of Moyamoya Angiopathy and Related Vascular Diseases.

Authors:  Kirsten B Dorschel; John E Wanebo
Journal:  Appl Clin Genet       Date:  2021-03-18

Review 3.  Single Nucleotide Polymorphism in Patients with Moyamoya Disease.

Authors:  Young Seok Park
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

Review 4.  Moyamoya disease and syndromes: from genetics to clinical management.

Authors:  Stéphanie Guey; Elisabeth Tournier-Lasserve; Dominique Hervé; Manoelle Kossorotoff
Journal:  Appl Clin Genet       Date:  2015-02-16

5.  Integrated Analysis of LncRNA-mRNA Co-Expression Profiles in Patients with Moyamoya Disease.

Authors:  Wen Wang; Faliang Gao; Zheng Zhao; Haoyuan Wang; Lu Zhang; Dong Zhang; Yan Zhang; Qing Lan; Jiangfei Wang; Jizong Zhao
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

6.  Construction and Comprehensive Analysis of Dysregulated Long Noncoding RNA-Associated Competing Endogenous RNA Network in Moyamoya Disease.

Authors:  Xuefeng Gu; Dongyang Jiang; Yue Yang; Peng Zhang; Guoqing Wan; Wangxian Gu; Junfeng Shi; Liying Jiang; Bing Chen; Yanjun Zheng; Dingsheng Liu; Sufen Guo; Changlian Lu
Journal:  Comput Math Methods Med       Date:  2020-06-13       Impact factor: 2.238

7.  CRISPR Detection and Research on Screening Mutant Gene TTN of Moyamoya Disease Family Based on Whole Exome Sequencing.

Authors:  Yilei Xiao; Weidong Liu; Jiheng Hao; Qunlong Jiang; Xingbang Wang; Donghu Yu; Liyong Zhang; Zhaogang Dong; Jiyue Wang
Journal:  Front Mol Biosci       Date:  2022-03-09

8.  The GC + CC genotype at position -418 in TIMP-2 promoter and the -1575GA/-1306CC genotype in MMP-2 is genetic predisposing factors for prevalence of moyamoya disease.

Authors:  Young Seok Park; Young Joo Jeon; Hyun Seok Kim; In Bo Han; Seung-Hun Oh; Dong-Seok Kim; Nam Keun Kim
Journal:  BMC Neurol       Date:  2014-10-04       Impact factor: 2.474

9.  Serum miRNA signature in Moyamoya disease.

Authors:  Dongwei Dai; Qiong Lu; Qinghai Huang; Pengfei Yang; Bo Hong; Yi Xu; Wenyuan Zhao; Jianmin Liu; Qiang Li
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

10.  Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.

Authors:  Hélène Choquet; Eliana Trapani; Luca Goitre; Lorenza Trabalzini; Amy Akers; Marco Fontanella; Blaine L Hart; Leslie A Morrison; Ludmila Pawlikowska; Helen Kim; Saverio Francesco Retta
Journal:  Free Radic Biol Med       Date:  2016-01-19       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.